MedTrace Logo

Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis

NCT02353039 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2015-07-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the investigational products in the patients with gastritis during their participation in the study.

Conditions

  • Gastritis

Interventions

DRUG

GC6101A 37.5mg

Administer 12.5mg of GC6101A t.i.d for 2 weeks.

DRUG

GC6101A 75mg

Administer 25mg of GC6101A t.i.d for 2 weeks.

DRUG

GC6101A 150mg

Administer 50mg of GC6101A t.i.d for 2 weeks.

DRUG

Placebo

Administer placebo t.i.d for 2 weeks

Sponsors & Collaborators

  • C&R Research, Inc.

    collaborator INDUSTRY

  • CRScube

    collaborator UNKNOWN

  • Green Cross Corporation

    lead INDUSTRY

Principal Investigators

  • Hyo Jin Park, MD, Ph.D · Yonsei University, Gangnam Severance Hospital of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02353039 on ClinicalTrials.gov